Cognito Therapeutics Secures $105 Million in Series C Funding to Advance Alzheimer's Therapy

Cognito Therapeutics Secures $105 Million in Series C Funding to Advance Alzheimer's Therapy

Cognito Therapeutics, a neurotechnology company based in Cambridge, Massachusetts, has successfully raised $105 million in a Series C funding round. The company is focused on developing treatments aimed at improving the health and well-being of individuals living with Alzheimer's disease. This latest funding round was led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital, with additional participation from New Vintage, Apollo Health Ventures, and Benvolio Group.

Advancing Alzheimer's Therapy

Cognito Therapeutics is at the forefront of creating non-invasive therapies for neurodegenerative diseases, particularly Alzheimer's disease. Their lead product, Spectris, is an investigational at-home therapeutic platform. It utilizes non-invasive visual and auditory stimulation to engage neural networks, aiming to preserve cognitive function, daily activities, and brain structure in Alzheimer’s patients. The company is currently in the late clinical stages and plans to use the newly raised capital to advance the Spectris platform.

Strategic Use of Funds

The $105 million raised will support several key initiatives for Cognito Therapeutics:

• Clinical Development and Data Readout: The funds will be used to support ongoing clinical development, including a pivotal clinical data readout expected later this year.
• Regulatory Submission and Commercial Launch: Cognito is preparing for a regulatory submission and anticipates a commercial launch of the Spectris platform in 2027.
• Expansion into Additional Indications: The company plans to expand its research into other neurodegenerative conditions through collaborations, such as with the WVU Rockefeller Neuroscience Institute.

Leadership and Vision

The leadership team at Cognito Therapeutics includes Angela Silva, who handles Executive Operations from the Office of the CEO, and Christian Howell, the Chief Executive Officer. Howell commented on this significant milestone, stating, "With this financing, we are entering a pivotal moment for our company, and for the patients and families waiting for new options in Alzheimer’s disease."

Looking Ahead

As Cognito Therapeutics moves forward with its plans, the company remains focused on its mission to develop disease-modifying treatments that can significantly impact the lives of those affected by Alzheimer's disease. The ongoing development of the Spectris platform and the preparation for its commercial launch reflect the company’s commitment to providing innovative solutions for neurodegenerative diseases.